Abstract 5908
Background
BPM31510-IV is an ubidecarenone containing intravenous nanodispersion targeting the metabolic machinery in cancer, shifting bioenergetics from lactate dependency towards mitochondrial OxPhos and reversing the Warburg effect. BPM31510-IV enables delivery of ubidecarenone preferentially into cancer cell mitochondria, generating reactive oxygen species and activation of apoptosis. In a phase I study, BPM31510-IV was well-tolerated as a monotherapy, and in combination with gemcitabine, with an established maximum tolerated dose (MTD) of 110mg/kg and thus, formed the basis for the Phase 2 investigation.
Trial design
In this study eligible patients (aged ≥ 18 y) relapsed/refractory to standard treatment for advanced metastatic pancreatic cancer and meeting inclusion/exclusion criteria receives either two 72 hr infusions of 110mg/kg BPM31510-IV or in combination with gemcitabine (1000 mg/m3 over 30 min, weekly x 3 weeks every 28 days). Tumor response is evaluated at wk 10, and then every 8 wks. This study occurs in two parts: Part 1 is designed to enroll 10 patients in the BPM31510-IV (monotherapy arm) and 10 patients in the BPM31510-IV plus gemcitabine (combination therapy arm) with intent to enroll an additional 15 patients (Part 2) into the applicable treatment arm(s). Endpoints will include overall response rate in both groups along with overall survival, progression-free survival, and time to progression. Additionally, patient reported Quality of Life using the validated FACT-HEP as well as tumor response measured by CA 19-9 levels will be combined with multi-omic molecular profiling to assess adaptive molecular responses. An exploratory objective of this study is to comprehensively perform multi-omic profiling for identification of biomarker panels for patient stratification for later stages of clinical development.
Clinical trial identification
NCT02650804.
Legal entity responsible for the study
BERG, LLC.
Funding
BERG, LLC.
Editorial Acknowledgement
Khampaseuth Thapa. BERG, LLC.
Disclosure
A.A. Niewiarowska, R. Ramanathan, P. Ritch: Research sponsorship: BERG, LLC. D.M. Lucius: Employee, stock owner: BERG, LLC. R. Sarangarajan: Co-founder, employee, stock options owner: BERG, LLC. N.R. Narain: Co-founder, president & CEO, stock options owner: BERG, LLC. J. Strauss: Research sponsorship: BERG, LLC; stock & other ownership: Abbott, Abbvie, Bristol-Myers Squibb, Intuitive surgical, Merck. M. Kundranda: Research sponsorship: BERG, LLC; Honoraria: Bayer. D. Propper: Research sponsorship: BERG, LLC; Consulting, advisory role: BMS; Speaker\'s bureau: Merck; Travel, accommodations, expenses: Celgene.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract